VolitionRx (NYSE:VNRX) Rating Lowered to “Hold” at Maxim Group

VolitionRx (NYSE:VNRX) was downgraded by stock analysts at Maxim Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, MarketBeat reports.

VNRX has been the subject of a number of other research reports. HC Wainwright dropped their target price on VolitionRx from $2.50 to $1.50 and set a “buy” rating for the company in a report on Monday, November 17th. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a research report on Wednesday, November 26th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, VolitionRx presently has an average rating of “Buy” and an average price target of $3.17.

VolitionRx Stock Up 9.5%

VolitionRx stock opened at $0.31 on Wednesday. The firm has a fifty day simple moving average of $0.43 and a two-hundred day simple moving average of $0.58. VolitionRx has a twelve month low of $0.27 and a twelve month high of $0.94. The company has a market capitalization of $38.24 million, a PE ratio of -0.86 and a beta of 1.26.

Insider Buying and Selling

In related news, CEO Cameron John Reynolds acquired 110,000 shares of VolitionRx stock in a transaction on Tuesday, October 14th. The shares were acquired at an average cost of $0.51 per share, with a total value of $56,100.00. Following the transaction, the chief executive officer owned 2,534,847 shares in the company, valued at $1,292,771.97. This trade represents a 4.54% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Guy Archibald Innes bought 96,153 shares of the company’s stock in a transaction dated Tuesday, October 14th. The stock was bought at an average cost of $0.51 per share, with a total value of $49,038.03. Following the completion of the transaction, the director owned 1,062,967 shares in the company, valued at approximately $542,113.17. This trade represents a 9.95% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 289,229 shares of company stock valued at $146,557. 10.40% of the stock is owned by corporate insiders.

Institutional Trading of VolitionRx

A number of hedge funds have recently modified their holdings of the business. Blair William & Co. IL bought a new position in shares of VolitionRx in the 2nd quarter worth about $30,000. Virtu Financial LLC purchased a new stake in VolitionRx in the third quarter worth about $28,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of VolitionRx during the second quarter valued at approximately $52,000. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of VolitionRx by 42.8% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock valued at $153,000 after purchasing an additional 60,209 shares during the last quarter. Finally, Citadel Advisors LLC lifted its holdings in shares of VolitionRx by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock valued at $224,000 after purchasing an additional 135,775 shares during the last quarter. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.